Please ensure Javascript is enabled for purposes of website accessibility

NW Bio granted cell production patent

Northwest Biotherapeutics Inc., of Bethesda, a biotechnology company developing personalized immune therapies for solid tumor cancers, announced that it has been issued a U.S. patent covering novel processes for manufacturing human dendritic cells.

Dendritic cells are cells that are important components of the body’s immune system.

The company said the cells produced through its patented processes are much more potent in their capacity to activate the immune system than those produced by the standard methods used throughout academia and industry to produce dendritic cells.

The patent has also been issued in Europe, Japan, Australia, New Zealand, India, China, Korea, Singapore, Russia and other countries.